| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.21▼ | 2.21▼ | 2.21▼ | 2.20▼ | 2.29▼ |
| MA10 | 2.27▼ | 2.27▼ | 2.27▼ | 2.27▼ | 2.40▼ |
| MA20 | 2.38▼ | 2.37▼ | 2.36▼ | 2.34▼ | 2.22▼ |
| MA50 | 2.43▼ | 2.45▼ | 2.46▼ | 2.41▼ | 2.11▼ |
| MA100 | 2.53▼ | 2.58▼ | 2.50▼ | 2.15▼ | N/A |
| MA200 | 2.61▼ | 2.60▼ | 2.41▼ | 2.11▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.029▼ | -0.024▼ | -0.023▼ | -0.032▼ | -0.015▼ |
| RSI | 30.457▼ | 33.127▼ | 33.988▼ | 41.404▼ | 47.510▼ |
| STOCH | 4.667▼ | 4.667▼ | 4.667▼ | 20.053 | 28.209 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -86.667▼ | -67.500 |
| CCI | -121.682▼ | -117.275▼ | -120.293▼ | -156.852▼ | -116.134▼ |
| MA | $BCG Price Crossed Below MA(200) | Set Alert |
|
Wednesday, February 18, 2026 06:43 AM
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa ...
|
|
Tuesday, February 17, 2026 05:44 AM
ImmunityBio shares climb in Tuesday's premarket after Saudi regulators encourage a key cancer treatment submission amid BCG shortages.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/02/26 | 2.17 | 2.18 | 2.09 | 2.09 | 5,100 |
| 13/02/26 | 2.02 | 2.23 | 2.02 | 2.17 | 4,800 |
| 12/02/26 | 2.3001 | 2.31 | 2.03 | 2.053 | 6,340 |
| 11/02/26 | 2.32 | 2.35 | 2.275 | 2.29 | 7,600 |
| 10/02/26 | 2.2662 | 2.45 | 2.2662 | 2.41 | 4,610 |
| 09/02/26 | 2.34 | 2.379 | 2.26 | 2.26 | 8,500 |
| 06/02/26 | 2.455 | 2.455 | 2.31 | 2.35 | 7,581 |
| 05/02/26 | 2.40 | 2.41 | 2.25 | 2.27 | 10,346 |
| 04/02/26 | 2.435 | 2.45 | 2.35 | 2.40 | 6,133 |
| 03/02/26 | 2.42 | 2.545 | 2.40 | 2.42 | 5,657 |
|
|
||||
|
|
||||
|
|